Zhejiang Hisun Pharmaceutical (SHA:600267) obtained approval from China's Ministry of Agriculture and Rural Affairs for two veterinary drugs, according to a Shanghai bourse filing on Friday.
The certificate for compound nystatin ointment and toltrazuril suspension, which is used to treat otitis externa in dogs and cats, is valid until Sept. 4, 2030.
The second certificate was for toltrazuril suspension, which is used to prevent coccidiosis in piglets and calves, and it is valid until Oct. 23, 2030.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments